MedWatch

Sydbank positive despite muted growth for Darzalex

Partner J&J's interim report shows that sales of Genmab’s cancer drug Darzalex doubled in Q3. However, the growth rate is lower compared to earlier this year, whivh has caused a drop in  Genmab's share price. But despite the cancer hope’s failure to meet expectations, Sydbank still calls the development positive.

Foto: Genmab, PR

Genmab’s multiple myeloma drug Darzalex, to which Johnson & Johnson holds the exclusive rights, is still doing well on the market. Johnson & Johnson’s Q3 interim report shows that sales of Darzalex have almost doubled compared to the same period last year.

Altogether Darzalex generated revenue of USD 317 million in the third quarter of 2017 relative to USD 163 million in the same period of 2016. This is a sales growth of 94.5 percent.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier